EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chromosome 10 (7+/10−), and TERT promoter mutation (pTERTmut) are alterations frequently observed in adult IDH-wild-type (IDHwt) glioblastoma (GBM). In the absence of endothelial proliferation and/or necrosis, these alterations currently are considered to serve as a surrogate for upgrading IDHwt diffuse or anaplastic astrocytoma to GBM. Here, we set out to determine the distribution of EGFRamp, 7+/10−, and pTERTmut by analyzing high-resolution copy-number profiles and next-generation sequencing data of primary brain tumors. In addition, we addressed the question whether combinations of partial gains on chromosome 7 and partial losses on chromosome 10 exhibited a diagnostic and prognostic value similar to that of complete 7+/10−. Several such combinations proved relevant and were combined as the 7/10 signature. Our results demonstrate that EGFRamp and the 7/10 signature are closely associated with IDHwt GBM. In contrast, pTERTmut is less specific for IDHwt GBM. We conclude that, in the absence of endothelial proliferation and/or necrosis, the detection of EGFRamp is a very strong surrogate marker for the diagnosis of GBM in IDHwt diffuse astrocytic tumors. The 7/10 signature is also a strong surrogate marker. However, care should be taken to exclude pleomorphic xanthoastrocytoma. pTERTmut is less restricted to this entity and needs companion analysis by other molecular markers to serve as a surrogate for diagnosing IDHwt GBM. A combination of any two of EGFRamp, the 7/10 signature and pTERTmut, is highly specific for IDHwt GBM and the combination of all three alterations is frequent and exclusively seen in IDHwt GBM.
Introduction
Isocitrate dehydrogenase IDH-wild-type (IDHwt) diffuse and anaplastic astrocytoma are considered provisional entities in the World Health Organization (WHO) classification of central nervous system tumors 2016 [20] . They comprise biologically and clinically different tumors, with the majority exhibiting molecular alterations and survival characteristics of IDHwt glioblastoma (GBM). A pressing question is whether EGFR amplification, the presence of combined gains on chromosome 7 and losses on chromosome 10, and TERT promoter mutation can serve as surrogate markers for 1 3 upgrading IDHwt astrocytomas corresponding histologically to WHO grade II or III to GBM, WHO grade IV.
The combination of gains on chromosome 7 and losses on chromosome 10 is characteristic molecular alterations in IDHwt GBM. Recent studies have demonstrated that astrocytic tumors not fulfilling the morphological criteria for GBM but carrying typical molecular features of GBM exhibit a clinical course similar to that of morphologically unequivocal GBM [5, 11, 24, 31, 32] . Therefore, the presence of combined chromosome 7 gains and chromosome 10 losses is considered as a molecular marker for IDHwt GBM. However, little is known about the relevance of assessing individual arms of chromosomes 7 and 10, i.e., does gain of either arm of 7 and loss of either arm of 10 suffice or is gain of both arms of chromosome 7 (trisomy 7) and loss of both arms of chromosome 10 (monosomy 10) required. Gains of chromosome 7 and losses of chromosome 10 in GBM have been initially detected by cytogenetic analyses [25] [4] . The typical constellation found in GBM cell lines was trisomy of chromosomes 7 and monosomy of chromosome 10, most likely as a result of errors in mitotic disjunction.
EGFR amplification (EGFRamp) in GBM has been initially observed by molecular and cytogenetic analyses [18, 34] [3, 9] . Roughly half of all GBM exhibit a high-level amplification of this gene mostly associated with the presence of double minutes, i.e., extrachromosomal elements containing additional EGFR copies [28] .
Telomerase reverse transcriptase (TERT) encodes the catalytic subunit of the telomerase complex. TERT promoter mutation (pTERTmut) initially has been detected in melanoma [12, 13] . Subsequent investigations also revealed high frequencies of pTERTmut in IDHwt GBM as well as IDHmutant (IDHmut) and 1p/19q-codeleted oligodendroglioma. [1, 14, 15, 19, 21, 33] , and demonstrated its potential use for subgrouping of gliomas [2, 7, 8, 22] .
Recent technology developments allow for generating high-resolution copy-number profiles (CNP) of the human genome in tumor tissue based on next-generation sequencing or microarray analyses. We set out to assess the distribution of EGFRamp, 7+/10−, and pTERTmut in human brain tumors based on CNP generated from DNA methylation array data sets and from next-generation sequencing data. Furthermore, we explored the prognostic association of these alterations in brain tumors diagnosed as IDHwt diffuse or anaplastic astrocytoma WHO grade II or III.
Materials and methods

Patient cohorts
The present analyses are based on data from three cohorts available for analysis at the Department of Neuropathology of the University Heidelberg. For each patient in the three cohorts, 450K or 850K DNA methylation array data are available. All patients have received a DNA methylationbased diagnosis as previously described [6] .
Cohort 1 includes 2417 brain tumor patients for whom next-generation panel sequencing with a panel including the TERT gene and its promoter region has been performed. Cohort 1 was employed for determining the distribution of pTERTmut, EGFRamp and 7+/10− in human brain tumors. Table 1 lists the tumor diagnoses of the patients included in cohort 1 sorted by DNA methylationbased classification.
Cohort 2 includes 10,826 brain tumor patients whose tumors have been analyzed using the Illumina 450K or 850K platforms. This data set was used to assess the distribution of EGFRamp and 7+/10− in human brain tumors. Supplementary Table 1 lists all tumor diagnoses for the patients included in cohort 2 sorted by DNA methylationbased diagnosis [6] and the respective numbers of patients. Cohort 2 encompasses all patients from cohort 1. Details on DNA methylation classes can be obtained from http:// www.molec ularn europ athol ogy.org.
Cohort 3 comprises 939 patients from cohort 2 for whom survival data were available. In contrast to cohorts 1 and 2, the histological diagnosis according to WHO 2016 [20] including the diagnosis of IDHwt diffuse or anaplastic astrocytoma was the basis for survival analysis. Cohort 3 does not include patients diagnosed with GBM. There is a bias in cohort 3, because survival data have been acquired for specific tumor entities in the previous studies [30] . Distribution of respective methylation groups and alterations on chromosomes 7 and 10 as well as EGFR status are given in Supplementary Table 2.
Generation and scoring of CNPs and mutations
DNA methylation data were generated using the Illumina 450K or 850K/EPIC platforms as previously described [6] . The copy-number variation plots were generated from the same raw data using the 'conumee' R package in Bioconductor (http://www.bioco nduct or.orgpa ckage s/relea se/ bioc/html/conum ee.html). Figure 1 shows representative CNPs. Automated assessment of copy-number changes was performed using the results from conumee after an additional baseline correction. EGFRamp was called amplified if the respective probes exhibited an intensity higher than 0.6 on a log2-scale.
Panel sequencing was performed as previously reported [26] . pTERTmut was scored if ten or more reads were detected with a minimum of 10% of the reads showing either of the two TERT promoter mutations. 
Statistics
All patient data sets were retrospectively compiled. The size of the respective sets was determined by availability of data and not by a power calculation. OS times were analyzed by the Kaplan-Meier method. Software R version 3.4 was employed for all the analyses.
Results and discussion
Rationale and procedure
We aimed at contributing to the following three questions: (1) What is the incidence of combined 7/10 copy-number alterations, EGFRamp and pTERTmut in different types of human brain tumors? (2) Are these three alterations suitable surrogate markers for diagnosing IDHwt GBM even in the absence of necrosis and microvascular proliferation? (3) Which patterns of partial or complete chromosome 7 gains and chromosome 10 losses might be employed for diagnostic purposes? The first two questions have been addressed by analyzing a series of 2417 tumors (cohort 1) for which both the TERT promoter status and complete copy-number profiles were available (Table 1) . Question three was addressed by analyzing an extended set of 10,826 patients (cohort 2) with complete copy-number profiles available (Supplementary Table 1 ), and analyzing a subset thereof including 939 (cohort 3) patients with available overall survival data.
For all cohorts, both a histopathological and a DNA methylation-based diagnosis were available. According to the WHO classification 2016, IDHwt GBM includes the H3-G34-mutant GBM, while H3-K27M-mutant diffuse midline gliomas and IDHmut GBM have been separated as distinct entities from IDHwt GBM [20] . For all questions addressing association of the markers interrogated with survival, we adhered to the current WHO definition of IDHwt GBM (all analyses involving cohort 3). For determination of frequencies, we used the DNA methylation-based diagnosis as this is highly standardized and, therefore, more suitable for this type of question.
Defining the 7/10 status
An open question is whether 7+/10− is prognostically relevant in IDHwt astrocytic gliomas only if both arms of each chromosome are affected or also aberrations of only one arm of either chromosome are detectable. Furthermore, how much of each chromosome arm needs to be affected by copy-number changes to suffice for prognostic relevance. This question is of particular interest in light of many of the available data to date being based on focused FISH analysis and, therefore, not providing representative information on the extent of copy-number imbalances on each chromosome. Our approach is based on an array platform, thereby covering the entire chromosome arms with ten thousands of probes each. We selected two different thresholds with one being 50% and the other 80% of chromosomal representation on each arm being gained or lost for calling the respective alteration in cohort 1. Supplementary Table 1 provides an overview of 7+ and 10− combinations using both thresholds. In the predominant GBM subgroup characterized by gain of entire 7 and loss of entire 10, 1185 patients (75% of all GBM) scored positive with the 80% and 1265 patients (81% of all GBM) with the 50% threshold (Supplementary Table 1) . We, therefore, went on using the 50% threshold for all subsequent analyses. Of nine possible combinations exhibiting both, gain of at least one arm on 7 and loss of at least one arm on 10, 7+/10− represents the most frequent (1265/1598; 79%) constellation followed by 7+/10q− (87/1598; 5%), by 7p+/10− (74/1598; 5%) and by 7q+/10− (70/1598; 4%) (Supplementary Table 1 ). Next, we analyzed which variants of gains on chromosome 7 and losses on chromosome 10 were associated with unfavorable clinical outcome in IDHwt astrocytic glioma patients. To this end, we analyzed the respective combinations in patients from cohort 3.
Of the nine possible combinations of chromosome 7 gains and chromosome 10 losses, we encountered 7+/10− (n = 97), 7q+/10− (n = 12), 7+/10q− (n = 9), 7q+/10q− (n = 7), 7p+/10− (n = 3), both 7+/10p− and 7q+/10p− (n = 1), and both 7p+/10p and 7p+/10q− (n = 0) in patients from cohort 3. Survival analysis was performed for patients whose tumors carried the combinations 7+/10− (n = 97), 7q+/10− (n = 12), 7+/10q− (n = 9), 7q+/10q− (n = 7), and 7p+/10− (n = 3). Three combinations, 7+/10−, 7q+/10−, and 7+/10q−, were associated with poor survival similar to that of patients with GBM (Fig. 2a) . We, therefore, defined all patients with 7+/10−, 7+/10q−, and 7q+/10− as carrying the prognostic 7/10 signature. However, additional studies should be encouraged for evaluation of the prognostic power of the rare combinations of chromosome 7 gains and chromosome 10 losses. Noteworthy, DNA methylationbased classification identified 52 patients in cohort 3 without a 7/10 signature but with typical survival characteristics of Fig. 2 a OS in 939 patients (cohort 3) who have been diagnosed with IDHwt glioma, excluding GBM, stratified for different combinations of alterations of chromosomes 7 and 10. Of all possible combinations with losses on chromosomes 7 and 10, only 7+/10−, 7+/10q−, 7p+10−, 7q+/10q−, and 7q+/10− were represented more than three times. Survival of glioma patients with 7+/10−, 7+/10q−, and 7q+/10− was significantly worse than that of patients without these alterations. b OS in 167 patients from cohort 3 who, in addition, have received the classifier diagnosis GBM, IDHwt. DNA methylation-based classification identifies 52 additional patients without the 7/10 signature. The black graph is a reference series of additional 261 patients diagnosed with IDHwt GBM by both, histology and DNA methylation-based classification GBM (Fig. 2b, orange graph) , thus demonstrating the power of this method. This set exhibited pTERTmut in 52% (n = 25) comparable to 67% and EGFRamp in 25% (n = 52) lower than 36% seen in all GBM included in cohort 1. Only one of these patients was allotted to the methylation class GBM, IDHwt, H3.3 G34-mutant (Supplementary Table 3) .
Distribution of EGFRamp, 7/10 signature, and pTERTmut in human brain tumors
Comparison of the distribution of all three parameters was performed using cohort 2, although, for the distribution of EGFRamp and 7/10 signature, a higher resolution could be obtained from cohort 1. pTERTmut was observed in 363 of 544 (67%) GBM, IDHwt, in 95 of 120 (79%) oligodendrogliomas, IDHmut and 1p/19q-codeleted, in 12 of 17 (71%) melanomas, in 19 of 42 (45%) medulloblastomas of DNA methylation subclass SHH A, and in 7 of 34 (21%) pleomorphic xanthoastrocytomas (PXA). Fractions of pTERTmut tumors in entities with low mutation frequencies or entities with only a few tumors analyzed are given in Table 1 . Of the three parameters, pTERTmut exhibited highest sensitivity (67%) but lowest specificity (89%) for the identification of IDHwt GBM ( Table 2) .
The 7/10 signature was more specific for GBM being detected in 323 of 544 (59%) GBM, IDHwt, in 9 of 140 (6%) IDHmut anaplastic astrocytomas and GBM, and in 5 of 54 (9%) medulloblastoma of DNA methylation subgroup 4 ( Table 1) . Sensitivity was 59% and specificity was 98% for IDHwt GBM (Table 2) .
EGFRamp was observed in 196/544 (36%) GBM, IDHwt, showing lowest sensitivity (36%) but highest specificity (100%) for this entity (Table 2) .
Overall, pTERTmut (562/2417) is more frequent than EGFRamp (199/2417) and 7/10 (361/2417). The combinations of pTERTmut-EGFRamp (28 cases), pTERTmut-7/10 (146 cases), and EGFRamp-7/10 (30 cases) were strongly associated with GBM, IDHwt, and the triple combination of pTERTmut-7+/10−-EGFRamp (124 cases) was exclusively seen in this entity ( Table 1 ). The sensitivity of any combination of double or triple positives was 58% and the specificity was 99% ( Table 2) .
Distribution of EGFRamp, 7/10 signature, and pTERTmut across DNA methylation classes of IDHwt GBM Subdivision of IDHwt GBM by DNA methylation-based classification results in 7 subgroups. These subgroups exhibit striking differences in the frequencies of the three molecular parameters interrogated. Tumors of the DNA methylation class GBM, IDHwt, and H3.3 G34-mutant (n = 17) did not exhibit pTERTmut or EGFRamp. The 7/10 signature was observed only in four H3.3 G34-mutant GBM. This finding is quite similar to that in H3.3 K27-mutant diffuse midline gliomas and argues for separating the H3.3 G34-mutant GBM from the other IDHwt GBM. Tumors of the DNA methylation class glioblastoma, IDHwt, subclass MYCN (n = 22) exhibited pTERTmut and EGFRamp in less than a quarter of all cases and the 7/10 signature only in a single tumor. DNA methylation class glioblastoma, IDHwt, and subclass RTK I (n = 71) presented with pTERTmut in 55 cases (77%). A total of 18 (25%) tumors carried EGFRamp and 46 (65%) tumors carried the 7/10 signature. DNA methylation class glioblastoma, IDHwt, subclass RTK II (n = 203) constituted the most frequent GBM subgroup and presented with pTERTmut in 166 cases (83%), EGFRamp in 128 cases (63%), and the 7/10 signature in 160 cases (79%). The DNA methylation class glioblastoma, IDHwt, subclass RTK III (n = 23) was predominantly encountered in young patients and exhibited pTERTmut in 11 (48%), EGFRamp in 8 (35%), and 7/10 in 3 (13%) instances. The DNA methylation class glioblastoma, IDHwt, subclass mesenchymal (n = 157) was frequent, and included 123 tumors with pTERTmut (78%), 37 tumors with EGFRamp (24%), and 109 tumors with the 7/10 signature (69%). Finally, tumors falling into the DNA methylation class glioblastoma, IDHwt, subclass midline (n = 51), which is an as yet poorly characterized group of tumors with morphology and survival characteristics comparable to that of other types of IDHwt GBM [24] , exhibited pTERTmut in only four tumors (8%), while EGFRamp and the 7/10 signature was absent in this group. As IDHwt GBM comprises all these distinct DNA methylation subgroups, the sensitivity of EGFRamp, 7/10 signature, and pTERTmut-based grading is compromised by the low prevalence or absence in some of the molecular subgroups.
Diagnostic use of the three parameters EGFRamp, 7/10 signature, and pTERTmut A single molecular marker for diagnosing IDHwt GBM in the absence of microvascular proliferation and/or necrosis would be a major contribution to daily routine diagnostics. While EGFRamp, pTERTmut, or 7/10 signature is very good candidates, single use is not warranted for each of these parameters. pTERTmut obviously needs accompanying analysis for IDH1 or IDH2 mutation to exclude IDHmut and 1p/19q-codeleted oligodendroglioma and IDHmut astrocytoma. Also rare cases of medulloblastoma in adults [23] and anaplastic meningioma [10, 27] , as well as solitary fibrous tumor/hemangiopericytoma frequently carry pTERTmut and need to be distinguished by their distinct histologies and appropriate additional molecular tests. The presence of pTERTmut in PXA [16] should be addressed by testing for the BRAFV600E mutation, typical for the latter [29] . However, an overlap with the rare epithelioid GBM cannot be ruled out [17] . The 7/10 signature also needs an additional testing for IDH mutation to exclude IDH-mutant diffuse and anaplastic gliomas and for BRAF mutation as it might occasionally occur in PXA (Table 1) . EGFRamp, however, has the highest specificity (< 99%) of all three parameters for GBM and IDH mutation testing can separate the very rare occurrences in IDH-mutant glioma. Assuming a threshold for specificity of 99% a reasonable compromise, our data support the single use of EGFRamp detection or any double positive combination of the three parameters EGFRamp, pTERTmut, or 7/10 signature for upgrading IDHwt astrocytoma to IDHwt GBM. For the low sensitivity for EGFRamp, we suggest the assessment of all three parameters.
Conclusions
Our data support the use of the molecular alterations EGFRamp, pTERTmut, or the 7/10 signature as diagnostic biomarkers for the upgrading of IDHwt diffuse astrocytoma WHO grade II or anaplastic astrocytoma WHO grade III to IDHwt GBM WHO grade IV, pending additional molecular tests. EGFRamp and the combination of a positive finding for any two of the three markers are highly specific for IDHwt GBM, while the combination of all three markers is exclusively seen in IDHwt GBM.
